Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms
19 September 2023 - 10:00PM
Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial
Biology Company®, today highlighted the industry-leading scale and
speed in whole-slide, spatial biology workflows enabled by the
recently launched PhenoCycler®-Fusion 2.0 and PhenoImager® HT 2.0
platform upgrades. Enhancements to the PhenoCycler-Fusion 2.0
System allow customers to process twice as many samples per week,
making it the highest throughput spatial discovery platform on the
market. The PhenoImager 2.0 platform delivers a 5x workflow
improvement by enabling rapid real-time image analysis directly on
the HT instrument. With an unprecedented ability to perform
whole-slide spatial biology at scale, Akoya’s customers can
accelerate progress towards new discoveries, identification of
clinically relevant biomarkers, and development of novel spatial
signatures.
“Our commitment to ongoing innovation and technical leadership
in spatial biology, consistent market performance, and a strong
intellectual property portfolio positions Akoya extremely well for
continued long term growth,” said Brian McKelligon, CEO of Akoya
Biosciences. “We look forward to supporting and enabling our
next 1000 customers and 1000 publications.”
The 2.0 enhancements, combined with Akoya’s PhenoCode™ Discovery
and Signature Panels, and proprietary file compression and rapid
image analysis, simplify and accelerate spatial biology workflows
from panel development and validation to data analysis. The 2.0
Platforms are now actively being installed as field upgrades on
existing systems, providing customers with immediate benefits in
throughput expansion and a significant reduction in time from
sample to answer.
“Since upgrading to the PhenoCycler-Fusion 2.0, our throughput
has doubled. The multi-slide functionality and other time-saving
improvements have resulted in tremendous benefits. The capability
to acquire whole-slide, processed, multiplexed imaging data at this
pace is truly phenomenal,” said John Hickey, PhD, Postdoctoral
Fellow, Department of Microbiology and Immunology at Stanford
University School of Medicine. “This enables the acquisition of
single-cell data across millions of cells spatially, which is
needed for robust spatial studies.”
“The PhenoImager HT 2.0 upgrade increases our workflow
efficiency and helps achieve reproducible and reliable high-plex
imaging by effectively eliminating signal crosstalk. This allows us
to expedite the development and execution of complex high-plex
multiplex projects for our customers while maintaining high-quality
standards,” said Linh Hoang, M.D., Ph.D., CEO of digital
histopathology service provider HistoWiz.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is
to bring context to the world of biology and human health through
the power of spatial phenotyping. The Company offers comprehensive
single-cell imaging solutions that allow researchers to phenotype
cells with spatial context and visualize how they organize and
interact to influence disease progression and response to therapy.
Akoya offers a full continuum of spatial phenotyping solutions to
serve the diverse needs of researchers across discovery,
translational and clinical research: PhenoCode™ Panels and
PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments.
To learn more about Akoya, visit www.akoyabio.com.
Investor Contact:
Priyam ShahSr. Director, Investor RelationsAkoya
Biosciencesinvestors@akoyabio.com
Media Contact:
Christine Quern617-650-8497media@akoyabio.com
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Apr 2024 to May 2024
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From May 2023 to May 2024